Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Emergent typhoid vaccination performs well in test
The phase II study, conducted under a company-sponsored IND led by Dr Beth Kirkpatrick at the University of Vermont, evaluated the safety and immunogenicity of the vaccine in
The phase II study, conducted under a company-sponsored IND led by Dr Beth Kirkpatrick at the University of Vermont, evaluated the safety and immunogenicity of the vaccine in
Momenta is developing its version, M-Enoxaparin, in collaboration with Sandoz, the generics division of Novartis AG. The companies will hope to take a slice of the worldwide sales
Preclinical studies have indicated that Amplimexon is effective at killing ovarian cancer cells in doses which can be achieved following administration of the drug to humans. In addition,
Products designated as orphan drugs are those that are being developed to treat diseases affecting fewer than 200,000 people in the US. The Orphan Drug Act guarantees seven
The goal of this project is to genetically engineer inter-alpha-inhibitor proteins (I(alpha)Ip) that have been found valuable as a treatment for sepsis in preclinical studies. Presently the only
This first phase II clinical study for the daily hydromorphone patch comprised a three day randomized dose-response study in opioid naive patients with acute pain following knee or
“We expect that this trial will continue to demonstrate the important difference that Delex’s particular approach makes to patients with its pulmonary delivery of opioids when compared to
According to the company, Servier has previously successfully identified and validated therapeutic compounds from Tripos’ LeadQuest compound collection. As a result of this, Servier has now chosen to
The application seeks US marketing approval for the use of Erbitux in combination with radiation, and with recurrent and/or metastatic head and neck cancer where prior platinum-based chemotherapy
Under the terms of the proposed acquisition, payments to Artesian shareholders are contingent on the achievement of certain pre-defined clinical milestones. The milestone payments are $32 million for